Axsome Therapeutics AXSM announced that it has dosed the first patient in the phase III SUMMIT study evaluating AXS-05 for ...

While smoking rates in the United States have substantially declined over the past six decades, smoking remains high among people with low incomes, leading to health disparities. A smartphone app that ...

NEW YORK, Aug. 31, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment ...

A new JAMA paper says nicotine e-cigarettes should be part of conversations about quitting cigarettes.Researchers reviewed ...

A telehealth-based smoking cessation program significantly improved quit rates among patients with cancer treated at community practices.A randomized trial showed patients who received the virtual ...

IQWiG has now published its final benefit assessment of bupropion, cytisine, nicotine and varenicline for smoking cessation, also in combination with each other, compared with no drug therapy.

LOS ANGELES — Treating nicotine addiction with glucagon-like peptide 1 receptor agonists (GLP-1 RAs) was associated with less weight gain compared with other smoking cessation treatments such as ...

Long-term data from the Copenhagen City Heart Study linked both current and former smoking with a higher risk of sudden ...

Dublin, June 20, 2025 (GLOBE NEWSWIRE) -- The "Smoking Cessation Aids Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced ...

The Canadian Vaping Association welcomed the latest update of the Cochrane living systematic review on electronic cigarettes for smoking cessation, which concludes with high-certainty evidence that ...